Allstate Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Allstate Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$503K	Buy	+4,215	New	+$494K	0.02%	495

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Allstate Investment Management's NBIX Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2022: 4,215 shares worth $503K. The stake represents 0.02% of the portfolio and ranks #495 among its holdings.

529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Allstate Investment Management held 4,215 shares of Neurocrine Biosciences worth $503K as of Q4 2022.
Neurocrine Biosciences was a new Allstate Investment Management position in Q4 2022.
Neurocrine Biosciences made up 0.02% of Allstate Investment Management's portfolio in Q4 2022, its #495 holding.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.